In accordance with Biovitrum stock option program 2006:2 TO3
2006/2008, 250 502 new shares have been issued at the price SEK 59.00
per share, resulting in Biovitrum being provided funds of a total of
SEK 14 779 618.00. No stock options remain in the stock option
program 2006:2 TO3 2006/2008.
After the share issue the outstanding number of shares in Biovitrum
is 46 015 624.
For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68
Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com
About Biovitrum
Biovitrum is a pharmaceutical company with operations in Sweden and
in the UK. The company markets a range of specialist pharmaceuticals
primarily in the Nordic countries. Using its expertise and experience
Biovitrum takes scientific innovation all the way to the market and
to specialist indication patients with significant medical need.
Research expertise and capabilities include development and
production of biotechnology therapeutics, as well as small molecule
discovery and development. With revenues of approximately SEK 1.3
billion and around 500 employees, Biovitrum is a significant European
specialty pharmaceutical player. It is listed on the OMX Nordic
Exchange in Stockholm. For more information go to www.biovitrum.com.
